NeuroPace Inc. (NPCE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NeuroPace: Only For Those With Strong Nerves
NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. NeuroPace stock is displaying substantial volatility and looks interesting on a highly speculative basis, anticipating wider approval of RNS.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Robert Marcus - JP Morgan Michael Polark - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
